Developing therapies for rare diseases involves complex incentives, unique requirements, and often extensive patient engagement. The authors of RAPS’ Orphan Drug Development for Rare Diseases, Sundar ...
The US Food and Drug Administration (FDA) is more likely to approve drugs with an orphan designation that were indicated for ...
Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational drug, riliprubart, for the treatment of antibody-mediated rejection (AMR) in solid organ transplantation.
LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological ...
DUBLIN--(BUSINESS WIRE)--The "Orphan Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Orphan Drugs was estimated at US$179.5 ...
It takes more than 21 months for a new orphan drug to reach Sweden, the average time to availability has risen by 153 days ...
The One Big Beautiful Bill Act takes a big step in the rare disease space by expanding the contours of the orphan drug exclusion, a once narrow exception that permitted manufacturers of rare disease ...
Spokane city employees face a 36% increase in health insurance premiums in the coming years as City Hall grapples with soaring pharmaceutical costs, particularly for a category of prescriptions called ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results